Abstract
Immune-mediated rippling muscle disease (iRMD) is a rare myopathy characterized by abnormal muscle excitability. It is usually electrically silent, exhibiting wavelike muscle contractions (rippling) and percussion- or stretch-induced muscle mounding.1 In contrast to hereditary rippling muscle disease (hRMD), associated to date with pathogenic variants in caveolin-3 (CAV3) or, less frequently, cavin-1 (CAVIN1) genes, patients with iRMD lack a defined genetic defect.2,3 Responsiveness to immunotherapy supports an autoimmune pathogenesis. Muscle acetylcholine receptor antibody positivity with or without clinical myasthenia gravis (MG) has been reported in association with iRMD, further favoring its potential immune-mediated etiology.4-6

This publication has 29 references indexed in Scilit: